Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Bevacizumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 314,411Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Avastin

    02 2Avastin

    03 2Aybintio

    04 4Mvasi

    05 2Pobevcy

    06 4Zirabev

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Avastin

    Bevacizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Avastin

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Bevacizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 7,285

    2018 Revenue in Millions : 7,054

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Mvasi

    Bevacizumab-awwb

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Mvasi

    U.S.A
    arrow
    BioAsia
    Not Confirmed

    Amgen

    Bevacizumab-awwb

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 798

    2019 Revenue in Millions : 127

    Growth (%) : 528

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Zirabev

    Bevacizumab-bvzr

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Zirabev

    U.S.A
    arrow
    BioAsia
    Not Confirmed

    Pfizer Inc.

    Bevacizumab-bvzr

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 143

    2019 Revenue in Millions : 1

    Growth (%) :

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Avastin

    Bevacizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Avastin

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Bevacizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 5,562

    2019 Revenue in Millions : 7,881

    Growth (%) : -29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Mvasi

    Bevacizumab-awwb

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Mvasi

    U.S.A
    arrow
    BioAsia
    Not Confirmed

    Amgen

    Bevacizumab-awwb

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,166

    2020 Revenue in Millions : 798

    Growth (%) : 46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Zirabev

    Bevacizumab-bvzr

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Zirabev

    U.S.A
    arrow
    BioAsia
    Not Confirmed

    Pfizer Inc.

    Bevacizumab-bvzr

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 444

    2020 Revenue in Millions : 143

    Growth (%) : 210

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Avastin

    Bevacizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Avastin

    Switzerland
    arrow
    BioAsia
    Not Confirmed

    Roche

    Bevacizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 3,289

    2020 Revenue in Millions : 5,292

    Growth (%) : -39

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Mvasi

    Bevacizumab-awwb

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Mvasi

    U.S.A
    arrow
    BioAsia
    Not Confirmed

    Amgen

    Bevacizumab-awwb

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 901

    2021 Revenue in Millions : 1,166

    Growth (%) : -23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Pobevcy

    Bevacizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Pobevcy

    China
    arrow
    BioAsia
    Not Confirmed

    BeiGene

    Bevacizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 40

    2021 Revenue in Millions : 1

    Growth (%) : 2,599

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Aybintio

    Bevacizumab

    arrow
    BioAsia
    Not Confirmed

    Brand Name : Aybintio

    U.S.A
    arrow
    BioAsia
    Not Confirmed

    Organon

    Bevacizumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 39

    2021 Revenue in Millions : 36

    Growth (%) : 8

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF